Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a pressing public health issue associated with ...

Glucagon-like peptide 1 receptor agonists and fenofibrates may protect patients with type 2 diabetes against diabetic macular ...

The term "nonalcoholic fatty liver disease" (NAFLD) has long been used to describe liver steatosis not related to excessive alcohol consumption ...

The new guidance includes updates on diabetes technology use, GLP-1 receptor agonists, liver disease, drinking water, and ...

GLP-1 drugs are quickly becoming some of the most ubiquitous in the U.S., and they have drawn interest for their potential ...

Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...

Namely, these are Leptin, a hormone that suppresses appetite; and glucagon-like peptide-1 or GLP-1, the hormone that tells ...

GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...

In addition, the decline in overall obesity rate reported by the CDC isn’t the first such drop. Between 1999 and 2018, the ...

Semaglutide use in diabetes patients is linked to a higher risk of NAION, a rare eye condition. A Danish-Norwegian study ...

But it might also trigger feelings of nausea. Another theory is that GLP-1s (glucagon-like peptide-1 receptor agonists) — the ...